Transfusion and Apheresis Science
Volume 28, Issue 1 , Pages 81-89 , February 2003

Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma

References 

  1. Edelson RL, Berger CL, Gasparro FP, et al.  Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N. Engl. J. Med. 1987;316:297–303
  2. Knobler RM, Girardi M. Extracorporeal photochemoimmunotherapy in cutaneous T cell lymphomas. Ann. N.Y. Acad. Sci. 2001;941:123–138
  3. Knobler RM, Trautinger F, Graninger W, et al.  Parenteral administration of 8-methoxypsoralen in photopheresis. J. Am. Acad. Dermatol. 1993;28:580–584
  4. Knobler RM, Edelson RL. Cutaneous T-cell lymphoma. Med. Clin. North Am. 1986;70:109–138
  5. Knobler RM. Photopheresis––extracorporeal irradiation of 8-MOP containing blood––a new therapeutic modality. Blut. 1987;54:247–250
  6. Berger CL, Perez M, Laroche L, Edelson RL. Inhibition of autoimmune disease in a murine model of systemic lupus erythematosus induced by exposure to syngeneic photoinactivated lymphocytes. J. Invest. Dermatol. 1990;94:52–57
  7. Berger CL, Wang N, Christensen I, et al.  The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens. J. Invest. Dermatol. 1996;107:392–397
  8. Edelson R. Light activated drugs. Sci. Am. 1988;259:68–75
  9. Gasparro FP, Song J, Knobler RM, Edelson RL. Quantitation of psoralen photoadducts in DNA isolated from lymphocytes treated with 8-methoxypsoralen and ultraviolet a radiation extracorporeal photopheresis. Curr. Probl. Dermatol. 1986;15:67–84
  10. Gasparro FP, Dall’Amico R, O’Molley M, Heald PW, Edelson RL. Cell membrane DNA: a new target for psoralen photoadduct formation. Phochem. Photobiol. 1990;52:315–321
  11. Perez M, Edelson RL, Laroche L, Berger C. Inhibition of antiskin allograft immunity by infusions with syngeneic photoinactivated effector lymphocytes. J. Invest. Dermatol. 1989;92:669–676
  12. Vowels BR, Cassin M, Boufal MH, Webster LJ, Rook AR. Extracorporeal photo-chemotherapy induces the production of tumor necrosis factor-α by monocytes: implications for the treatment of cutaneous T-cell lymphoma and systemic sclerosis. J. Invest. Dermatol. 1992;96:686–692
  13. Gasparro FP, Berger CL, Edelson RL. Effect of monochromatic UVA light and 8-methoxypsoralen on human lymphocyte response to mitogen. Photodermatol. 1984;1:10–17
  14. Santella RM, Dharmaraja N, Gasparro FP, Edelson RL. Monoclonal antibodies to DNA modified by 8-methoxypsoralen and ultraviolet a light. Nucleic Acids Res. 1985;13:2533–2544
  15. Schmitt IM, Moor AC, Patrignelli R, et al.  Increased surface expression of class I MHC molecules on immunogenic cells derived from the xenogenization of P815 mastocytoma cells with 8-methoxypsoralen and long-wavelenght ultraviolet radiation. Tissue Antigens. 1995;46:45–49
  16. Reinisch W, Nahavandi H, Santella R, et al.  Extracorporeal photochemotherapy in patients with steroid-dependent Crohn’s disease: a prospecive pilot study. Aliment. Pharmocol. Ther. 2001;15:1313–1322
  17. Sumpio BE, Phan SM, Gasparro FP, Deckelbaum LI. Control of smooth muscle cell proliferation by psoralen photochemotherapy. J. Vasc. Surg. 1993;17:1010–1016
  18. Trautinger F, Knobler RM, Macheiner W, Grunwald C, Micksche M. Release of oxygen-free radicals by neutrophils is reduced by photopheresis. Ann. NY Acad. Sci. 1991;636:383–385
  19. van Iperen HP, Beijersbergen van Henegouwen GM. Animal model for extracorporeal photochemotherapy based on contact hypersensitivity. J. Photochem. Photobiol. Biol. 1992;15:361–366
  20. Yamane Y, Lobo FM, John LA, Edelson RL, Perez MI. Suppression of anti-skin-allograft response by photodamaged effector cells––the modulating effects of prednisone and cyclophosphamide. Transplantation. 1992;54:119–124
  21. Rook A, Prystowsky MB, Cassin M, Boufal M, Lessin RS. Combined therapy for Sezary syndrome with extracorporeal photochemotherapy and low-dose interferon alfa therapy. Arch. Dermatol. 1991;127:1535–1540
  22. Duvic M, Hester JP, Lemak NA. Photopheresis therapy for cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 1996;35:573–579
  23. Zic J, Stricklin GP, Greer JP, et al.  Long term follow-up with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. J. Am. Acad. Dermatol. 1996;356:935–945
  24. Gottlieb S, Wolfe J, Fox FE, et al.  Treatment of Cutaneous T-cell lymphoma with Extracorporeal Photopheresis Monotherapy and in Combination with Recombinant interferon alpha: A 10 year Experience at a single Institution. J. Am. Acad. Dermatol. 1996;35:946–957
  25. Cohen J, Lessin SR, Vowels BR, et al.  The sign of Leser-Trelat in association with Sezary syndrome: simultaneous disappearance of seborrheic keratoses and malignant T-cell clone during combined therapy with photopheresis and interferon alfa. Arch. Dermatol. 1993;129:1213–1215
  26. Frieden T, Bia FJ, Heald PW, et al.  Cutaneous cryptococcosis in a patient with cutaneous T-cell lymphoma receiving therapy with photopheresis and methotrexate. Clin. Infect. Dis. 1993;17:776–778
  27. Fraser-Andrew E, Seed P, Whittaker S, Russel-Jones R, et al.  Extracorporeal photopheresis in Sézary syndrome. Arch. Dermatol. 1998;134:1001–1005
  28. Russel-Jones R. Extracorporeal photopheresis in cutaneous T-cell lymphoma inconsistent data underline the need for randomized studies. Brit. J. Dermatol. 2000;142:16–21
  29. Rook AR, Suchin KR, Kao DM, et al.  Photopheresis: clinical applications and mechanism of action. J. Invest. Dermatol. Symp. Proc. 1999;4:85–90
  30. Russel-Jones AR. Extracorporeal photopheresis in Sézary syndrome. Lancet. 1997;350:886
  31. Willemze R, Kerl H, Sterry W, et al.  EORTC classification for primary cutaneous lymphomas: a proposal from the cutaneous lymphoma study group of the European Organization for Research and Treatment of Cancer. Blood. 1997;90:354–371
  32. Fimiani M, Rubegni P, De Aloe G, Andreassi L. Role of extracorporeal photochemotherpy alone and in combination with interferon alfa in the treatment of cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 1999;41:502–503
  33. Vonderheid EC, Bigler RD, Greenberg AS, Neubaum SJ, Micaily B. Extracorporeal photopheresis and recombination interferon alfa b in Sezary syndrome: use of dual marker labeling to monitor therapeutic response. Am. J. Clin. Oncol. 1994;17:255–263
  34. Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol. Oncol. North Am. 1995;9:1089–1107
  35. Dippel E, Goerdt S, Assaf C, Stein H, Orfanos CE. Extracorporeal photopheresis and interferon-α in advanced cutaneous T-cell lymphoma. Lancet. 1997;350:32–33
  36. Jumbou O, N’Guyen JM, Tessier MH, Legoux B, Dreno B, Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by Interferon-alfa . Br. J. Dermatol. 1999;140:427–431
  37. Haley HR, Davis DA, Sams WM. Durable lose of malignant T-cell clone in a stage IV cutaneous T-cell lymphomas patient treated with high-doses interferon and photopheresis. J. Am. Acad. Dermatol. 1999;41:880–883
  38. Zackheim HS. Evidence is lacking for a synergistic or additive effect of combination extracorporeal photopheresis with interferon alfa for cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 2000;42:1087–1088
  39. Heald PW, Perez MI, Christensen I, Dobbs N, McKieman G, Edelson R. Photopheresis therapy in cutaneous T-cell lymphoma: The Yale New Haven Hospital Experience. Yale J Biol Med. 1989;61:629–638
  40. Rook AH, Gottlieb SL, Wolfe JT, et al.  Pathogenesis of cutaneous T-cell lymphoma: implication for the use of recombinant cytokines and photopheresis. Clin. Exp. Immunol. 1997;107:16–20
  41. Rook AH, Wood GS, Yoo EK, et al.  Interleukin 12 induces lesion regression and cytotoxic T-cell responses in cutaneous T-cell lymphomas. Blood. 1999;94:902–908
  42. Wilson LD, Licola AL, Braverman IM. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. Int. J. Rad. Oncol. Biol. Phys. 1995;32:987–995
  43. Vonderheid EC. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 1988;38:207–220
  44. Koh HK. Extracorporeal photopheresis for the treatment of 34 patients with cutaneous T-cell lymphoma (CTCL). J. Invest. Dermatol. 1994;2:260
  45. Wilson LD, Jones WD, Kim D, et al.  Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythodermic (T4) mycosis fungoides. J. Am. Acad. Dermatol. 2000;43:54–60
  46. Berger CL, Wang N, Christensen I, et al.  The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens. J. Invest. Dermatol. 1996;107:392–397
  47. Hanlon DJ, Berger CL, Edelson RL. Photoavtivated 8-methoxypsoralen treatment causes a peptide-dependent increase in antigen display by transformed lymphocytes. Int. J. Cancer. 1998;76:70–75
  48. Berger CL, Longley BJ, Imaeda S, et al.  Tumor-specific peptides in cutaneous T-cell lymphoma: association with class I major histocompatibility complex and possible derivation from the clonotypic T-cell receptor. Int. J. Cancer. 1998;76:304–311
  49. Berger CL, Xu AL, Hanlon D. Induction of human tumor-loaded dendritic cells. Int. J. Cancer. 2001;91:438–447
  50. Bisaccia E, Gonzalez J, Palangio M, Schwartz J, Klainer AS. Extracorporeal photochemotherapy alone or with adjuvante therapy in the treatment of cutaneaous T-cell lymphoma: A 9-year retrospective study at a single institution. J. Am. Acad. Dermatol. 2000;43:263–271
  51. Jiang SB, Dietz SB, Kim M, Lim HW, Extracorporeal photochemotherapy for cutaneous T-cell lymphoma: a 9.7-year experience . Photodermatol. Photoimmunol. Photomed. 1999;15:161–165
  52. Wollina U, Looks A, Meyer J, et al.  Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial. J. Am. Acad. Dermatol. 2001;44:253–260
  53. Prinz B, Behrens W, Holzle E, Plewig G. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma: the Düsseldorf and Munich experience. Arch. Dermatol. Res. 1995;287:1–6
  54. Crovetti G, Carabelli A, Berti F, et al.  Photopheresis in cutaneous T-cell lymphoma: five-year experience. Int. J. Artif. Organs. 2000;23:55–62
  55. Dall’Amico R, Zacchello G, Heald P. Applicazione della fotoferesis nella terapia di malattie oncologiche ed autiommuni. (The application of photopheresis in the therapy of cancerous and autoimmune disease). Recenti. Prog. Med. 1991;82:294–299
  56. Owsianowski M, Garbe C, Ramaker J, Orfanos CE, Gollnick H. Therapeutische Erfahrungen mit der Extracorporalen Photopherese. Hautarzt. 1996;47:114–123
  57. Zouboulis CC, Schmuth M, Doepfner S, Dippel E, Orfanos CE. Extracorporeal photopheresis of cutaneous T-cell lymphoma is associated with reduction of peripheral CD4+T lymphocytes. Dermatology. 1998;196:305–308
  58. Konstantinow A, Balda BR. Treatment of cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J. Eur. Acad. Dermatol. Venerol. 1996;9:111–117
  59. Girardi M, Schechner J, Glusac E, Berger C, Edelson R. Transimmunization and the evolution of extracorporeal photochemotherapy. Tranfus. Apheresis Sci. 2002;26:181–190

PII: S1473-0502(02)00103-9

doi: 10.1016/S1473-0502(02)00103-9

Transfusion and Apheresis Science
Volume 28, Issue 1 , Pages 81-89 , February 2003

Article Tools